Storage and handling
Other information Store at room temperature 15°-30°C (59°-86°F)
Other information Store at room temperature 15°-30°C (59°-86°F)
Active ingredients Purpose
Polyethylene Glycol 400 0.4%................. Lubricant
Propylene Glycol 0.3%........................... Lubricant
Use
For the temporary relief of burning and irritation due to eye dryness
Warnings
For external use only
retain carton for full drug facts
Do not use
When using this product
Stop use and ask a doctor if
Keep out of reach of children
If swallowed get medical help or contact a Poison Control Center immediately
Directions
Other information
Store at room temperature 15°-30°C (59°-86°F)
Inactive ingredients boric acid, calcium chloride, chlorhexidine, glyconate, hydrochloric acid, hypromellose 2910, magnesium chloride, potassium chloride, purified water, sodium chloride, sodium hydroxide, zinc chloride
Distributed by:
CVS Pharmacy, Inc.
One CVS Drive
Woonsocket, RI 02895
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 477589 | polyethylene glycol 400, 0.4 % / propylene glycol 0.3 % Ophthalmic Solution | PSN | 1 |
| 477589 | polyethylene glycol 400 4 MG/ML / propylene glycol 3 MG/ML Ophthalmic Solution | SCD | 1 |
| 477589 | PEG 400 0.4 % / propylene glycol 0.3 % Ophthalmic Solution | SY | 1 |
| Resource | Code type | Value | Equivalent identifiers | Source image |
|---|---|---|---|---|
| Barcode | EAN-13 | 0050428496497 | GTIN-13: 0050428496497 EAN-13: 0050428496497 GTIN-12: 050428496497 UPC-A: 050428496497 GTIN storage (14 digits): 00050428496497 | PA 49649.01 PL CVS LL Dry Eye Twin Pack Systane _TB_CT_OL.jpg |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 59779-496-30 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-cac3-f424-e053-dadaa90a57ce | 56862988-2b5e-4510-b46d-d2325ffefe19 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 59779-496-30 | CVS Long Lasting Lubricant Eye Twin Pack | 15 mL in 1 BOTTLE, DROPPER | SOLUTION/ DROPS | 15 | 1 | |
| 59779-496-30 | CVS Long Lasting Lubricant Eye Twin Pack | 2 in 1 CARTON | SOLUTION/ DROPS | 2 | 1 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| POLYETHYLENE GLYCOL 400 | ACTIVE INGREDIENT | B697894SGQ | 1 | |
| PROPYLENE GLYCOL | ACTIVE INGREDIENT | 6DC9Q167V3 | 1 | |
| POLYETHYLENE GLYCOL 400 | ACTIVE MOIETY | B697894SGQ | 1 | |
| PROPYLENE GLYCOL | ACTIVE MOIETY | 6DC9Q167V3 | 1 | |
| BORIC ACID | INACTIVE INGREDIENT | R57ZHV85D4 | 1 | |
| CALCIUM CHLORIDE | INACTIVE INGREDIENT | M4I0D6VV5M | 1 | |
| CHLORHEXIDINE GLUCONATE | INACTIVE INGREDIENT | MOR84MUD8E | 1 | |
| HYDROCHLORIC ACID | INACTIVE INGREDIENT | QTT17582CB | 1 | |
| MAGNESIUM CHLORIDE | INACTIVE INGREDIENT | 02F3473H9O | 1 | |
| POTASSIUM CHLORIDE | INACTIVE INGREDIENT | 660YQ98I10 | 1 | |
| SODIUM CHLORIDE | INACTIVE INGREDIENT | 451W47IQ8X | 1 | |
| SODIUM HYDROXIDE | INACTIVE INGREDIENT | 55X04QC32I | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 | |
| ZINC CHLORIDE | INACTIVE INGREDIENT | 86Q357L16B | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 59779-496 | 59779-496-30 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| POLYETHYLENE GLYCOL 400 | B697894SGQ | ACTIB |
| PROPYLENE GLYCOL | 6DC9Q167V3 | ACTIB |
| BORIC ACID | R57ZHV85D4 | IACT |
| CALCIUM CHLORIDE | M4I0D6VV5M | IACT |
| CHLORHEXIDINE GLUCONATE | MOR84MUD8E | IACT |
| HYDROCHLORIC ACID | QTT17582CB | IACT |
| MAGNESIUM CHLORIDE | 02F3473H9O | IACT |
| POTASSIUM CHLORIDE | 660YQ98I10 | IACT |
| WATER | 059QF0KO0R | IACT |
| SODIUM CHLORIDE | 451W47IQ8X | IACT |
| SODIUM HYDROXIDE | 55X04QC32I | IACT |
| ZINC CHLORIDE | 86Q357L16B | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | GEL / TRANSDERMAL | 472 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / EPIDURAL | 0.9 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INFILTRATION | 648 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | LIQUID / ORAL | 4.46 mg/1ml | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SUSPENSION/ DROPS / OPHTHALMIC | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / TOPICAL | 39 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / RECTAL | NA | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | CONCENTRATE / ORAL | 2.17 mg/1ml | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | GRANULE, FOR SUSPENSION / ORAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | LIQUID / TOPICAL | ADJ PH | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | SUSPENSION / ORAL | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION/ DROPS / OPHTHALMIC | 3 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SUSPENSION / SUBCUTANEOUS | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION/ DROPS / OPHTHALMIC | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SOLUTION / INTRATHECAL | ADJ PH | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, FILM COATED / ORAL | 100 mg | ||
| MAGNESIUM CHLORIDE | MAGNESIUM CHLORIDE | 02F3473H9O | SOLUTION / OPHTHALMIC | 0.01 %w/v | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | LIQUID / INTRAMUSCULAR | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, FOR SOLUTION / INTRATUMOR | ADJ PH | ||
| BORIC ACID | BORIC ACID | R57ZHV85D4 | SOLUTION/ DROPS / OPHTHALMIC | 48 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / INTRAVASCULAR | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION / ORAL | 400 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRAMUSCULAR | 78 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SPONGE / TOPICAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SOLUTION, CONCENTRATE / INTRAVENOUS | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / SUBCUTANEOUS | ADJ PH | ||
| ZINC CHLORIDE | ZINC CHLORIDE | 86Q357L16B | INJECTION / SUBCUTANEOUS | 0.02 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SUSPENSION / INTRA-ARTICULAR | 45 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | GEL / TOPICAL | 70 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / EPIDURAL | 648 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / RESPIRATORY (INHALATION) | ADJ PH | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SUSPENSION / SUBCUTANEOUS | NA | ||
| ZINC CHLORIDE | ZINC CHLORIDE | 86Q357L16B | TABLET / ORAL | 14 mg | ||
| BORIC ACID | BORIC ACID | R57ZHV85D4 | SOLUTION / OPHTHALMIC | 60 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTERSTITIAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SUSPENSION / INTRAVENOUS | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION/ DROPS / AURICULAR (OTIC) | ADJ PH | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / ORAL | 1126 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR | 0.35 %w/v | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, FOR SOLUTION / PARENTERAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SYRUP / ORAL | 2.03 mg/1ml | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / EPIDURAL | 3535 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | DROPS / NASAL | 10 ml | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / INTRAPERITONEAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SUSPENSION / INTRASYNOVIAL | ADJ PH | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / INTRAPERITONEAL | 0.54 %w/v | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRATHECAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | CAPSULE / ORAL | 60 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / SOFT TISSUE | ADJ PH | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 226 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTABLE, LIPOSOMAL / INTRAVENOUS | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / EPIDURAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / RETROBULBAR | ADJ PH | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / SUBARACHNOID | 0.9 %w/v | ||
| BORIC ACID | BORIC ACID | R57ZHV85D4 | JELLY / VAGINAL | 1 %w/w | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / NASAL | 7.4 mg/1ml | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRAVENOUS | 720 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / OPHTHALMIC | 0.31 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION / INTRAMUSCULAR | 26 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| d05ff791-57fd-46f5-93b5-a6f796be7d37 | 56862988-2b5e-4510-b46d-d2325ffefe19 | 2014-07-10 | Warnings | d05ff791-57fd-46f5-93b5-a6f796be7d37 56862988-2b5e-4510-b46d-d2325ffefe19 |
Adverse event summaries are temporarily unavailable. Other product information remains available.